Recent advances in systemic therapy for advanced biliary tract cancer: A systematic review and meta-analysis using reconstructed RCT survival data
Background & Aims: Gemcitabine/cisplatin (GemCis) was the long-standing first-line treatment for advanced biliary tract cancers (BTCs). Following positive results from the TOPAZ-01 and KEYNOTE-966 trials, immune checkpoint inhibitors (ICIs) combined with chemotherapy are now the standard of...
Saved in:
Main Authors: | Zhihao Li, Daniel Aliseda, Owen Jones, Luckshi Rajendran, Christian Magyar, Robert Grant, Grainne M. O’Kane, Anna Saborowski, Gonzalo Sapisochin, Arndt Vogel |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-03-01
|
Series: | JHEP Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2589555924002945 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Immune Landscape and Its Potential for Immunotherapy in Advanced Biliary Tract Cancer
by: Andry Santoso, et al.
Published: (2024-12-01) -
Somatic Mutations from Whole Exome Sequencing Analysis of the Patients with Biliary Tract Cancer
by: Kyong-Ah Yoon, et al.
Published: (2018-12-01) -
First-line chemotherapy with selective internal radiation therapy for intrahepatic cholangiocarcinoma: The French ACABi GERCOR PRONOBIL cohort
by: Nicolas Adamus, et al.
Published: (2025-02-01) -
Integration of circulating tumor DNA in biliary tract cancer: the emerging landscape
by: Joy A Awosika, et al.
Published: (2024-12-01) -
Biliary diseases (<i>Review of the Seventeenth Russian Gastroenterological Week proceedings, October, 10–12, 2011, Moscow</i>)
by: I. V. Mayev, et al.
Published: (2012-06-01)